US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
0.2810
-0.0016 (-0.57%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stocks That Hit 52-Week Lows On Monday
↗
May 23, 2022
On Monday, 149 companies reached new 52-week lows.
Via
Benzinga
7 Cheap Biotech Stocks to Buy Now
↗
May 19, 2022
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.
Via
InvestorPlace
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer
May 02, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
↗
April 16, 2022
Deals, financings, trials and approvals in biotech in China this week.
Via
Talk Markets
VistaGen Appoints Reid Adler as Chief Legal Officer
May 02, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses
April 21, 2022
Via
Investor Brand Network
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
April 21, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Recap: VistaGen Therapeutics Q3 Earnings
↗
February 10, 2022
VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 10, 2022
↗
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
April 12, 2022
Via
Investor Brand Network
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
April 12, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference
March 24, 2022
Via
Investor Brand Network
Stocks That Hit 52-Week Lows On Tuesday
↗
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
March 14, 2022
On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
March 07, 2022
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 17, 2022
Gainers Creative Medical Tech (NASDAQ:CELZ
Via
Benzinga
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
↗
February 14, 2022
According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
February 22, 2022
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to...
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update
February 11, 2022
Via
Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call
February 07, 2022
Via
Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18
November 16, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights
November 11, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update
November 04, 2021
Via
Investor Brand Network
VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
↗
October 14, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
October 14, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity
October 05, 2021
Via
Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
August 26, 2021
Gainers MorphoSys (NASDAQ:MOR) stock move...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
August 13, 2021
Gainers Cellect Biotechnology (NASDAQ:APOP
Via
Benzinga
Recap: VistaGen Therapeutics Q1 Earnings
↗
August 12, 2021
Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the...
Via
Benzinga
Looking Into VistaGen Therapeutics's Return On Capital Employed
↗
July 13, 2021
In Q4, VistaGen Therapeutics (NASDAQ:VTGN) posted sales of $441.90 thousand. Earnings were up 17.36%, but VistaGen Therapeutics still reported an overall loss of $6.22 million....
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
